Inovio Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy INO?
Source: Globenewswire
- Class Action Filed: A securities class action lawsuit has been initiated in the U.S. District Court for the Eastern District of Pennsylvania against Inovio Pharmaceuticals, covering all investors who purchased the company's securities between October 10, 2023, and December 26, 2025, indicating significant investor dissatisfaction with the company's transparency.
- Allegations of Manufacturing Deficiencies: The complaint alleges that Inovio failed to disclose manufacturing deficiencies related to its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024, thereby impacting investor decision-making.
- Overstated Regulatory Prospects: The lawsuit further claims that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, suggesting that the company's regulatory and commercial prospects were significantly overstated, potentially leading to investor losses.
- Investor Rights Protection: Investors are encouraged to contact the law firm before the April 7, 2026, lead plaintiff motion deadline to protect their rights in the class action, highlighting the legal emphasis on safeguarding investor interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.660
Low
3.00
Averages
7.33
High
13.00
Current: 1.660
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: A securities class action lawsuit has been initiated in the U.S. District Court for the Eastern District of Pennsylvania against Inovio Pharmaceuticals, covering all investors who purchased the company's securities between October 10, 2023, and December 26, 2025, indicating significant investor dissatisfaction with the company's transparency.
- Allegations of Manufacturing Deficiencies: The complaint alleges that Inovio failed to disclose manufacturing deficiencies related to its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024, thereby impacting investor decision-making.
- Overstated Regulatory Prospects: The lawsuit further claims that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, suggesting that the company's regulatory and commercial prospects were significantly overstated, potentially leading to investor losses.
- Investor Rights Protection: Investors are encouraged to contact the law firm before the April 7, 2026, lead plaintiff motion deadline to protect their rights in the class action, highlighting the legal emphasis on safeguarding investor interests.
See More
Inovio Pharmaceuticals Faces Class Action for Investor Misleading
- Lawsuit Background: Robbins LLP has filed a class action against Inovio Pharmaceuticals, alleging that the company misled investors between October 10, 2023, and December 26, 2025, by failing to disclose manufacturing deficiencies in its CELLECTRA device, which led to delays in the INO-3107 FDA submission.
- Regulatory Delays: The submission of the INO-3107 Biologics License Application (BLA), initially expected in the second half of 2024, has been postponed to mid-2025 due to manufacturing issues, resulting in a misjudgment of the company's prospects by investors and directly impacting stock prices.
- Stock Price Volatility: Following the financial report on August 8, 2024, which revealed the delay, Inovio's stock price fell by 3.1% to $8.44 per share; on December 29, 2025, after the FDA accepted the application for standard review, the stock plummeted by 24.45% to $1.73 per share.
- Investor Rights: Robbins LLP is urging affected shareholders to participate in the lawsuit, as lead plaintiffs in the class action, emphasizing that investors do not need to participate in the case to be eligible for recovery, highlighting the importance of corporate governance and shareholder rights.
See More
Inovio Pharmaceuticals Faces Shareholder Class Action Lawsuit
- Lawsuit Allegations: Inovio Pharmaceuticals is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements regarding its CELLECTRA device's manufacturing deficiencies, which hindered its ability to submit the INO-3107 Biologics License Application (BLA) on time.
- Regulatory Outlook Deterioration: Due to these manufacturing issues, Inovio is unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024, potentially jeopardizing its eligibility for accelerated approval or priority review, which could adversely affect the company's market prospects.
- Investor Losses: Investors who purchased Inovio shares between October 10, 2023, and December 26, 2025, and experienced significant losses are encouraged to contact legal counsel to discuss their rights, reflecting growing investor anxiety about the company's future.
- Legal Representation: Holzer & Holzer, a law firm dedicated to shareholder litigation, has recovered hundreds of millions for defrauded investors in recent years, underscoring its commitment to protecting investor rights.
See More
Pomerantz LLP Investigates Inovio Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims of securities fraud against Inovio Pharmaceuticals, focusing on whether the company and its executives engaged in unlawful business practices, which could lead to significant investor losses.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but indicated that the company failed to provide adequate information for accelerated approval, highlighting serious regulatory hurdles.
- Stock Price Plunge: Following the FDA announcement, Inovio's stock price fell by $0.56, a 24.45% drop, closing at $1.73 per share, reflecting market pessimism regarding the company's future prospects.
- Future Plans: Inovio announced it does not plan to seek approval under the standard review timeline but intends to meet with the FDA to discuss how to pursue accelerated approval, a strategy that may significantly impact its future market performance.
See More
Inovalis REIT Completes Disposition of Trio Property
- Disposition Completed: Inovalis REIT announced the completion of the Trio property disposition, which had been reclassified as an asset held for sale in its financial statements as of September 30, 2025, and this transaction is expected to enhance financial stability.
- Loan Repayment: Proceeds from the disposition were used to repay the mortgage loan secured by the Trio property, with all related financing arrangements fully satisfied and discharged, thereby alleviating the REIT's financial burden.
- Occupancy Impact: At the time of disposition, the Trio property had an occupancy rate of approximately 40%, negatively impacting the REIT's cash flow, and this transaction is anticipated to improve overall cash flow conditions.
- LTV Reduction: The transaction reduced the REIT's overall loan-to-value (LTV) ratio by approximately 5% to 61.5%, aligning with its ongoing portfolio management strategy and reflecting a disciplined approach to asset management.
See More
Inovio Pharmaceuticals Under Investigation, Stock Plummets 24.45%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Inovio Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, but the company failed to provide adequate information for accelerated approval, highlighting regulatory compliance challenges.
- Stock Price Volatility: Following the FDA's review outcome, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on December 29, 2025, reflecting market pessimism about the company's future prospects.
- Uncertain Future Plans: Inovio announced it does not plan to seek approval under the standard review timeline and intends to meet with the FDA to discuss the possibility of accelerated approval, indicating uncertainty in its product launch strategy.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: A securities class action lawsuit has been initiated in the U.S. District Court for the Eastern District of Pennsylvania against Inovio Pharmaceuticals, covering all investors who purchased the company's securities between October 10, 2023, and December 26, 2025, indicating significant investor dissatisfaction with the company's transparency.
- Allegations of Manufacturing Deficiencies: The complaint alleges that Inovio failed to disclose manufacturing deficiencies related to its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024, thereby impacting investor decision-making.
- Overstated Regulatory Prospects: The lawsuit further claims that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, suggesting that the company's regulatory and commercial prospects were significantly overstated, potentially leading to investor losses.
- Investor Rights Protection: Investors are encouraged to contact the law firm before the April 7, 2026, lead plaintiff motion deadline to protect their rights in the class action, highlighting the legal emphasis on safeguarding investor interests.
See More
Inovio Pharmaceuticals Faces Class Action for Investor Misleading
- Lawsuit Background: Robbins LLP has filed a class action against Inovio Pharmaceuticals, alleging that the company misled investors between October 10, 2023, and December 26, 2025, by failing to disclose manufacturing deficiencies in its CELLECTRA device, which led to delays in the INO-3107 FDA submission.
- Regulatory Delays: The submission of the INO-3107 Biologics License Application (BLA), initially expected in the second half of 2024, has been postponed to mid-2025 due to manufacturing issues, resulting in a misjudgment of the company's prospects by investors and directly impacting stock prices.
- Stock Price Volatility: Following the financial report on August 8, 2024, which revealed the delay, Inovio's stock price fell by 3.1% to $8.44 per share; on December 29, 2025, after the FDA accepted the application for standard review, the stock plummeted by 24.45% to $1.73 per share.
- Investor Rights: Robbins LLP is urging affected shareholders to participate in the lawsuit, as lead plaintiffs in the class action, emphasizing that investors do not need to participate in the case to be eligible for recovery, highlighting the importance of corporate governance and shareholder rights.
See More
Inovio Pharmaceuticals Faces Shareholder Class Action Lawsuit
- Lawsuit Allegations: Inovio Pharmaceuticals is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements regarding its CELLECTRA device's manufacturing deficiencies, which hindered its ability to submit the INO-3107 Biologics License Application (BLA) on time.
- Regulatory Outlook Deterioration: Due to these manufacturing issues, Inovio is unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024, potentially jeopardizing its eligibility for accelerated approval or priority review, which could adversely affect the company's market prospects.
- Investor Losses: Investors who purchased Inovio shares between October 10, 2023, and December 26, 2025, and experienced significant losses are encouraged to contact legal counsel to discuss their rights, reflecting growing investor anxiety about the company's future.
- Legal Representation: Holzer & Holzer, a law firm dedicated to shareholder litigation, has recovered hundreds of millions for defrauded investors in recent years, underscoring its commitment to protecting investor rights.
See More
Pomerantz LLP Investigates Inovio Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims of securities fraud against Inovio Pharmaceuticals, focusing on whether the company and its executives engaged in unlawful business practices, which could lead to significant investor losses.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but indicated that the company failed to provide adequate information for accelerated approval, highlighting serious regulatory hurdles.
- Stock Price Plunge: Following the FDA announcement, Inovio's stock price fell by $0.56, a 24.45% drop, closing at $1.73 per share, reflecting market pessimism regarding the company's future prospects.
- Future Plans: Inovio announced it does not plan to seek approval under the standard review timeline but intends to meet with the FDA to discuss how to pursue accelerated approval, a strategy that may significantly impact its future market performance.
See More
Inovalis REIT Completes Disposition of Trio Property
- Disposition Completed: Inovalis REIT announced the completion of the Trio property disposition, which had been reclassified as an asset held for sale in its financial statements as of September 30, 2025, and this transaction is expected to enhance financial stability.
- Loan Repayment: Proceeds from the disposition were used to repay the mortgage loan secured by the Trio property, with all related financing arrangements fully satisfied and discharged, thereby alleviating the REIT's financial burden.
- Occupancy Impact: At the time of disposition, the Trio property had an occupancy rate of approximately 40%, negatively impacting the REIT's cash flow, and this transaction is anticipated to improve overall cash flow conditions.
- LTV Reduction: The transaction reduced the REIT's overall loan-to-value (LTV) ratio by approximately 5% to 61.5%, aligning with its ongoing portfolio management strategy and reflecting a disciplined approach to asset management.
See More
Inovio Pharmaceuticals Under Investigation, Stock Plummets 24.45%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Inovio Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, but the company failed to provide adequate information for accelerated approval, highlighting regulatory compliance challenges.
- Stock Price Volatility: Following the FDA's review outcome, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on December 29, 2025, reflecting market pessimism about the company's future prospects.
- Uncertain Future Plans: Inovio announced it does not plan to seek approval under the standard review timeline and intends to meet with the FDA to discuss the possibility of accelerated approval, indicating uncertainty in its product launch strategy.
See More
